Paper Details

  1. Home
  2. Paper Details

Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.

Author: AdvaniRanjana J, AnsellStephen M, BartlettNancy L, ChesonBruce D, ChristianBeth, DiefenbachCatherine S, FeldmanTatyana A, LaPlantBetsy, LeeHun J

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Hodgkin lymphoma is a cancer that can be cured. However, older patients often have a lower response rate to treatment and worse outcomes. Brentuximab vedotin and nivolumab are medications used to treat relapsed or refractory Hodgkin lymphoma. This study aims to evaluate the safety and effectiveness of these medications in older patients with Hodgkin lymphoma and in younger patients who are not suitable for standard treatment.
Paper Details　
Original Abstract of the Article :
Hodgkin lymphoma is potentially curable. However, 15-35% of older patients (ie, >60 years) have a lower response rate, worse survival outcomes, and greater toxicity than younger patients. Brentuximab vedotin and nivolumab exhibit activity in patients with relapsed or refractory Hodgkin lymphoma. We ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S2352-3026(20)30275-1

データ提供：米国国立医学図書館（NLM）

Brentuximab Vedotin Plus Nivolumab: A Promising Combination for First-Line Treatment of Hodgkin Lymphoma

Hodgkin lymphoma, a type of cancer affecting the lymphatic system, is a serious disease. While treatments have improved, challenges remain, particularly in older patients and those who cannot tolerate standard chemotherapy regimens. This study investigates the efficacy and safety of a combination therapy, brentuximab vedotin plus nivolumab, as a first-line treatment option for Hodgkin lymphoma in these high-risk patient populations.

A New Frontier in Hodgkin Lymphoma Treatment

This single-arm phase 2 clinical trial evaluated the combination of brentuximab vedotin and nivolumab in untreated older patients with Hodgkin lymphoma or younger patients ineligible for standard chemotherapy. The study found that this combination therapy was well-tolerated and showed promising efficacy, suggesting a potentially beneficial treatment option for these challenging patient populations.

Hope for a More Effective and Tolerable Treatment Approach

This research provides encouraging evidence for the potential of brentuximab vedotin plus nivolumab as a first-line treatment option for Hodgkin lymphoma in older patients and those who cannot tolerate standard chemotherapy. This new combination therapy may offer a more effective and tolerable alternative, potentially improving treatment outcomes and offering hope for a better future for these patients. This study represents a step forward in the ongoing fight against this devastating disease, akin to a desert traveler discovering a new route leading towards a more hopeful destination.

Dr. Camel's Conclusion

Hodgkin lymphoma, a formidable opponent, presents unique challenges for older patients and those who cannot tolerate standard chemotherapy. This research explores a new frontier in Hodgkin lymphoma treatment, combining brentuximab vedotin and nivolumab. This study, like a desert traveler seeking a new path, offers a glimmer of hope for a more effective and tolerable treatment approach for these patients.

Date :
  1. Date Completed 2020-10-29
  2. Date Revised 2020-10-29
Further Info :

Pubmed ID

33010817

DOI: Digital Object Identifier

10.1016/S2352-3026(20)30275-1

Related Literature

Article Analysis
・Effects of brentuximab vedotin injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.